OncoDaily’s Post

Dr. Ray Page, Director of Research, recently gave a scientific poster presentation of study results at the World Lung Cancer Conference. Dr. Page states, “This is an important study looking across 31 community oncology practices across the United States that are similar to our practice. We tested a Decision Support Program to accelerate the identification of a specific lung cancer mutation, called EGFR, that can best match oral drugs to treat this particular lung cancer, instead of receiving intravenous chemo in the chair. It was a positive study that should be expanded to other cancer centers to assure we are getting the best and most effective drugs to lung cancer patients.” #thecentertx #CancerWontWait #HopeIsHere

Short Report: The ADCs of Next-Gen Cancer Treatment--The antibody drug conjugate pipeline is a promise in the making for next-generation cancer treatment. With close to 100 candidates currently in Phases 2 and 3 clinical trials the industry is optimistic about the future of this versatile and robust therapy. Learn more about this next-generation cancer treatment in The Weekly Brief: https://lnkd.in/eCbZrP9. #ADC #Cancer #PharmaCircle

When 20% of patients don’t succeed with conventional cancer treatments, this is where we come into the picture! Having personally witnessed the devastating effects of inoperable cancer, I'm dedicated to transforming cancer care. At IntraGel Therapeutics we're pioneering minimally invasive interventional oncology to provide safe, life-saving alternatives for those who need them most. Watch this short video to learn more about our mission and how we're bringing new hope to millions of cancer patients #CancerTreatment #Oncology #Pharma #IntraGel

We are happy to announce our return to the "Invest in Oncology Forum" for the second time, where we will be among Nordic companies pioneering advanced therapies in the field of cancer. At the forum, we are excited to showcase the latest developments of iadademstat, the most potent LSD1 inhibitor currently in clinical development for cancer treatment. Specifically, we will highlight the progress of our ongoing FRIDA trial in AML R/R-Flt3+ patients. Furthermore, we are thrilled to introduce the first outcome of our CRADA collaborative efforts with the NCI-NIH. This collaboration has resulted in the initiation of the first clinical trial where we combine iadademstat with atezolizumab or durvalumab in 1L-ED SCLC patients. This marks a significant milestone in our commitment to advancing innovative treatment approaches in oncology. #LSD1 #epigenetics #personalizedmedicine #iadademstat #AML #SCLC #ICIs #gilteritinib #durvalumab #atezolizumab #oryzon 

Results from our Phase 3 clinical trial evaluating treatments for patients with advanced ALK-positive NSCLC shared at American Society of Clinical Oncology (ASCO) 2024 Albert Bourla Pfizer #ASCO24 #Cancer #LCSM #NSCLC #ClinicalTrials #OncoDaily #Oncology

🌍📊 Our international projections found that improving lung cancer screening programmes could increase the five-year survival rate by an estimated 73% in the first year across the seven geographies studied. 🫁✨ Members of the Lung Cancer Policy Network provided feedback on the methodology that informed these estimates. 💬 This formed a key discussion point at our recent round table event alongside the #WorldHealthAssembly. Explore how lives for those with lung cancer can be improved from earlier detection and treatment in Ti Hwei How's (VP International Oncology and Market Access AstraZeneca ) recent article with Devex:

Pharmacy Focus: Oncology Edition- Benefits of Subcutaneous Amivantamab for Lung Cancer Treatment: The PALOMA-3 trial showed subcutaneous amivantamab was better than IV among lung cancer patients. #finance #pharmacy #lifesciences

✨Last month, Dr Denis Lacombe, EORTC CEO, shared insights about the Cancer Medicines Forum during a live webinar hosted by The Cancer Drug Development Forum (CDDF). You can take a look at the key takeaways below. 👇   #CancerMedicinesForum #CancerResearch #ClinicalTrials #Oncology

Join the FDA Oncology Center of Excellence for a Conversation on Cancer on Feb. 1 in recognition of World Cancer Day. The conversation will focus on the introduction of certain innovative therapeutic classes in the past two decades that have revolutionized the care for patients with chronic myeloid leukemia, multiple myeloma, and melanoma. The discussion will provide an overview of regulatory programs that expedite access to patients, including FDA’s Breakthrough Therapy designation and Accelerated Approval; and the European Medicines Agency’s Prime and Conditional Approval. The panel of patients, investigators and regulators aims to highlight successes from development to approval. This is the second collaboration between OCE and the EMA in this public panel discussion series. Register here: https://lnkd.in/eNM-Gjns #OCEProjectCommunity #cancer #drugdevelopment #FDA #EMA

Oncology accounts for 43% of current and planned clinical trials. Cancer is not even a top 10 global cause of death, according to the WHO. Only in mid/high-income countries did a form of cancer (Lung, Colon) represent a top-10 cause of death. Out of the 33,594 ongoing or upcoming phase I-III clinical trials with publicly available data, Oncology trials make up nearly 43%. https://lnkd.in/dnis9xWt